Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
There has long been interest in innovating an approach by which tumor cells can be selectively and specifically targeted and destroyed. The discovery of viruses that lyse tumor cells, termed oncolytic viruses (OVs), has led to a revolution in the treatment of cancer. The potential of OVs to improve the therapeutic ratio is derived from their ability to preferentially infect and replicate in cancer cells while avoiding destruction of normal cells surrounding the tumor. Two main mechanisms exist through which these viruses are reported to improve outcomes: direct lysis of tumor cells and indirect augmentation of host anti-tumor immunity. With these factors in mind, viruses are chosen or modified to selectively target tumor cells, decrease pathogenicity to normal cells, decrease the antiviral immune response (to prevent viral clearance), and increase the antitumor immune response. While only one OV has been approved for the treatment of cancer in the United States, and only two other OVs have been approved worldwide, a wide spectrum of OVs are in various stages of preclinical development and in clinical trials. These viruses are being studied as alternatives and adjuncts to more traditional cancer therapies including surgical resection, chemotherapy, radiation, hormonal therapies, targeted therapies, and other immunotherapies. Here, we review the natural characteristics and genetically engineered modifications that enhance the effectiveness of OVs for the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642 · cited 1×
“These are described in this review, while other considerations, including bioavailability and safety have been described in detail in our earlier review (19).”
BackgroundSelf-citationCombining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586 · cited 1×
“In contrast, immunotherapy seeks to enhance the host immune system’s ability to eliminate cancer cells resulting in tumor regression, antitumor immune memory formation, and ultimately in durable responses (1, 2).”
BackgroundThe human CD46 molecule is a receptor for measles virus (Edmonston strain)
Dörig, R. E., Marcil, A., Chopra, A., & Richardson, C. D. (1993) · Cell · doi:10.1016/0092-8674(93)80071-l · Cited by 1,033 · cited 2×
“This can be taken advantage of by use of the measles virus (Edmonston strain) which utilizes CD46 for cell entry, making tumor cells overexpressing this receptor susceptible to oncolysis (21).”
BackgroundHeise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940 · cited 2×
“OVs ONYX-15 and H101 have been engineered to prevent expression of E1B (43).”
BackgroundTakaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847
Dmitriev, I., Krasnykh, V., Miller, C. R., Wang, M., Kashentseva, E., Mikheeva, G., Belousova, N., & Curiel, D. T. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9706-9713.1998 · Cited by 767
History of Oncolytic Viruses: Genesis to Genetic Engineering
Kelly, E., & Russell, S. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300108 · Cited by 763
Puzanov, I., Milhem, M. M., Minor, D., Hamid, O., Li, A., Chen, L., Chastain, M., Gorski, K. S., Anderson, A., Chou, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1529 · Cited by 562 · cited 2×
“Cancer Gene Ther (2004) 11(10): 643–64.”
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus
Strong, J. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3351 · Cited by 552 · cited 2×
“In cancer cells in which this pathway has been manipulated; however, the PKR pathway is not activated, which allows increased viral production and lysis (29).”
BackgroundPark, B.-H., Hwang, T., Liu, T.-C., Sze, D. Y., Kim, J.-S., Kwon, H.-C., Oh, S. Y., Han, S.-Y., Yoon, J.-H., Hong, S.-H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 521
Kaufman, H. L., Kim, D. W., DeRaffele, G., Mitcham, J., Coffin, R. S., & Kim-Schulze, S. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0809-6 · Cited by 518 · cited 1×
“Cell Death Differ (2012) 19(12):2003–14.”
O'Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, A. E., & Francis, G. E. (1999) · Human Gene Therapy · doi:10.1089/10430349950018021 · Cited by 409 · cited 1×
“Therefore, neutralizing antibodies may be present in the serum prior to treatment and further antibodies produced more rapidly based on immunological memory (55).”
BackgroundOncolytic Viruses and Their Application to Cancer Immunotherapy
Chiocca, E. A., & Rabkin, S. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0015 · Cited by 408
Markert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., Nabors, L. B., Markiewicz, M., Lakeman, A. D., Palmer, C. A., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.228 · Cited by 401
DeWeese, T. L., van der Poel, H. G., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U. M., DeJong, R., Detorie, N. A., Rodríguez, R., et al. (2001) · PubMed · Cited by 385
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation
Jouan-Lanhouet, S., Arshad, M. I., Piquet-Pellorce, C., Martin-Chouly, C., Le Moigne-Muller, G., Van Herreweghe, F., Takahashi, N., Sergent, O., Lagadic-Gossmann, D., Vandenabeele, P., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2012.90 · Cited by 357
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
Mastrangelo, M. J., Maguire, H. C., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700066 · Cited by 353 · cited 1×
“Similar modifications have been made in adenoviruses and vaccinia virus (59, 60).”
MethodNishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier-Hayes, L., Savoldo, B., & Dotti, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0697 · Cited by 331
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Bommareddy, P. K., Patel, A., Hossain, S., & Kaufman, H. L. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0238-9 · Cited by 322
Self-citationMarkert, J. M., Razdan, S. N., Kuo, H.-C., Cantor, A., Knoll, A., Karrasch, M., Nabors, L. B., Markiewicz, M., Agee, B. S., Coleman, J. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.22 · Cited by 319
Andtbacka, R. H. I., Ross, M., Puzanov, I., Milhem, M., Collichio, F., Delman, K. A., Amatruda, T., Zager, J. S., Cranmer, L., Hsueh, E., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5286-0 · Cited by 308
Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J.-S., Falls, T., Burns, J., Garcia, V., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.276 · Cited by 305 · cited 1×
“This leads to the increased production of virus and propagation of the infection (30).”
BackgroundCarlsten, M., Norell, H., Bryceson, Y. T., Poschke, I., Schedvins, K., Ljunggren, H.-G., Kiessling, R., & Malmberg, K.-J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901226 · Cited by 283 · cited 1×
“This receptor is frequently upregulated by cancers because it affords protection from innate immunity for the pathogen by downregulating antitumor natural killer (NK) cell responses (25).”
Background(1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4660 · Cited by 247
Ramesh, N., Ge, Y., Ennist, D. L., Zhu, M., Mina, M., Ganesh, S., Reddy, P. S., & Yu, D.-C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1059 · Cited by 242 · cited 1×
“Therefore, the E1A protein has been placed under the control of the E2F-1 promoter in this virus (40).”
BackgroundReddy, P. S., Burroughs, K. D., Hales, L. M., Ganesh, S., Jones, B. H., Idamakanti, N., Hay, C., Li, S. S., Skele, K. L., Vasko, A.-J., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm198 · Cited by 242 · cited 1×
“For example, Seneca valley virus is being clinically evaluated for its therapeutic efficacy against neuroendocrine tumors based on its natural tropism for cancer cells with neuroendocrine features (31, 32).”
BackgroundGulley, J. L., Arlen, P. M., Tsang, K.-Y., Yokokawa, J., Palena, C., Poole, D. J., Remondo, C., Cereda, V., Jones, J. L., Pazdur, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0126 · Cited by 228
Poppers, J., Mulvey, M., Khoo, D., & Mohr, I. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11215-11221.2000 · Cited by 223 · cited 1×
“These virulence factors are required in normal infection, but since tumor cells undergo aberrant division and frequently downregulate PKR, this attenuated virus is able to preferentially infect cancer cells (44).”
BackgroundLentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection
Morizono, K., Xie, Y., Ringpis, G.-E., Johnson, M., Nassanian, H., Lee, B., Wu, L., & Chen, I. S. Y. (2005) · Nature Medicine · doi:10.1038/nm1192 · Cited by 220 · cited 1×
“Similarly, to allow for targeting of melanoma by a lentivirus, the E2 glycoprotein of the Sindbis virus, which has a natural affinity to these cells, has been expressed (36).”
BackgroundKaufman, H. L., & Bines, S. D. (2010) · Future Oncology · doi:10.2217/fon.10.66 · Cited by 209 · cited 1×
“, fever, fatigue, and other flu-like symptoms) (78, 79).”
Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein
Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., & Wold, W. S. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.6147-6155.2000 · Cited by 206 · cited 1×
“Similar to HSV-1 TK, another viral suicide gene, adenovirus death protein has been incorporated into OVs in preclinical studies to increase cell death (49).”
BackgroundMader, E. K., Maeyama, Y., Lin, Y., Butler, G. W., Russell, H. M., Galanis, E., Russell, S. J., Dietz, A. B., & Peng, K.-W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1292 · Cited by 204 · cited 1×
“Other methods developed to avoid antibody neutralization include the encapsulation of OVs in polymer coatings to ensure viral replication and circulation (63, 64).”
MethodICAM-1 as a molecular target for triple negative breast cancer
Guo, P., Huang, J., Wang, L., Jia, D., Yang, J., Dillon, D. A., Zurakowski, D., Mao, H., Moses, M. A., & Auguste, D. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408556111 · Cited by 192
Oncolytic viruses: a novel form of immunotherapy
Prestwich, R. J., Harrington, K. J., Pandha, H. S., Vile, R. G., Melcher, A. A., & Errington, F. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.10.1581 · Cited by 180
Mansour, M., Palese, P., & Zamarin, D. (2011) · Journal of Virology · doi:10.1128/jvi.01537-10 · Cited by 168 · cited 1×
“This gives the virus time to incubate, multiply, and form syncytia, which is imperative to the survival and spread of Newcastle disease virus (28).”
BackgroundGalanis, E., Markovic, S. N., Suman, V. J., Nuovo, G. J., Vile, R. G., Kottke, T. J., Nevala, W. K., Thompson, M. A., Lewis, J. E., Rumilla, K. M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.146 · Cited by 168
Cell Carriers for Oncolytic Viruses: Fed Ex for Cancer Therapy
Willmon, C., Harrington, K., Kottke, T., Prestwich, R., Melcher, A., & Vile, R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.194 · Cited by 167
Noonan, A. M., Farren, M. R., Geyer, S. M., Huang, Y., Tahiri, S., Ahn, D., Mikhail, S., Ciombor, K. K., Pant, S., Aparo, S., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.66 · Cited by 166 · cited 2×
“Pancreatic Adenocarcinoma (13) Phase II 73 Addition of pelareorep to”
BackgroundShafren, D. R., Au, G. G., Nguyen, T. P., Newcombe, N. G., Haley, E. S., Beagley, L., Johansson, E., Hersey, P., & Barry, R. D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0690-3 · Cited by 158
Di Piazza, M., Mader, C., Geletneky, K., Herrero y Calle, M., Weber, E., Schlehofer, J., Deleu, L., & Rommelaere, J. (2007) · Journal of Virology · doi:10.1128/jvi.02601-06 · Cited by 155 · cited 1×
“Thus, H-1PV utilizes the cathepsin-mediated pathway to cause tumor cell death (45, 46).”
BackgroundRudin, C. M., Poirier, J. T., Senzer, N. N., Stephenson, J., Loesch, D. M., Burroughs, K. D., Reddy, P. S., Hann, C. L., & Hallenbeck, P. L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1706 · Cited by 153
Neuman, E., Flemington, E. K., Sellers, W. R., & Kaelin, W. G. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6607 · Cited by 144
Lin, E. E., & Nemunaitis, J. J. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700733 · Cited by 143 · cited 1×
“org September 2017 | Volume 7 | Article 202 cancer patients (3).”
BackgroundChimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
Xia, A., Wang, X., Lu, Y., Lu, X., & Sun, B. (2017) · Oncotarget · doi:10.18632/oncotarget.19361 · Cited by 140
Mell, L. K., Brumund, K. T., Daniels, G. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3232 · Cited by 136
Sova, P., Ren, X.-W., Ni, S., Bernt, K. M., Mi, J., Kiviat, N., & Lieber, A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.008 · Cited by 133
Li, J., Liu, H., Xr, Z., Xu, J.-P., Hu, W.-K., Liang, M., Chen, S.-Y., Hu, F., & Chu, D.-T. (2008) · Gene Therapy · doi:10.1038/gt.2008.179 · Cited by 132
Post, D. E., Sandberg, E. M., Kyle, M. M., Devi, N. S., Brat, D. J., Xu, Z., Tighiouart, M., & Meir, E. G. V. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3244 · Cited by 126 · cited 2×
“Specifically, HYPR-Ad is an adenovirus whose E1A expression is transcriptionally regulated by HIF-1α, a protein induced by the hypoxic environment (41).”
BackgroundOsteocalcin-directed gene therapy for prostate-cancer bone metastasis
Koeneman, K. S., Kao, C. H., Ko, S.-C., Yang, L., Wada, Y., Kallmes, D. F., Gillenwater, J. Y., Zhau, H. E., Chung, L. W. K., & Gardner, T. A. (2000) · World Journal of Urology · doi:10.1007/s003450050181 · Cited by 123
Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
Kaufman, H. L., Kim-Schulze, S., Manson, K., DeRaffele, G., Mitcham, J., Seo, K. S., Kim, D. W., & Marshall, J. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-60 · Cited by 116
Oncolytic viruses as immunotherapy: progress and remaining challenges
Aurelian, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s63049 · Cited by 112
Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma
Au, G. G., Lincz, L. F., Enno, A., & Shafren, D. R. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06550.x · Cited by 108
Nüesch, J. P. F., Lacroix, J., Marchini, A., & Rommelaere, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2325 · Cited by 106
Chang, J., Zhao, X., Wu, X., Guo, Y., Guo, H., Cao, J., Guo, Y., Lou, D., Yu, D., & Li, J. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.8.7913 · Cited by 96
Mahalingam, D., Fountzilas, C., Moseley, J., Noronha, N., Tran, H., Chakrabarty, R., Selvaggi, G., Coffey, M., Thompson, B., & Sarantopoulos, J. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3260-6 · Cited by 94
Kaufman, H. L., Cohen, S., Cheung, K., DeRaffele, G., Mitcham, J., Moroziewicz, D. N., Schlom, J., & Hesdorffer, C. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.239 · Cited by 77
Angelova, A. L., Grekova, S. P., Heller, A., Kuhlmann, O., Soyka, E., Giese, T., Aprahamian, M., Bour, G., Rüffer, S., Cziepluch, C., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03688-13 · Cited by 76 · cited 2×
“Thus, H-1PV utilizes the cathepsin-mediated pathway to cause tumor cell death (45, 46).”
BackgroundNeuman, E., Flemington, E. K., Sellers, W. R., & Kaelin, W. G. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6607-6615.1994 · Cited by 73 · cited 1×
“Normally, Rb binds to E2F, inhibiting this factor’s activity and its ability to conjugate with other molecules (39).”
BackgroundImmunological Effects of a Tumor Necrosis Factor Alpha–Armed Oncolytic Adenovirus
Hirvinen, M., Rajecki, M., Kapanen, M. K., Parviainen, S., Rouvinen-Lagerström, N., Diaconu, I., Nokisalmi, P., Tenhunen, M., Hemminki, A., & Cerullo, V. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.069 · Cited by 67
Oncolysis of human ovarian cancers by echovirus type 1
Shafren, D. R., Sylvester, D. E., Johansson, E., Campbell, I., & Barry, R. D. (2005) · International Journal of Cancer · doi:10.1002/ijc.20866 · Cited by 64 · cited 2×
“org September 2017 | Volume 7 | Article 202 (26).”
BackgroundIntratumoral Approaches for the Treatment of Melanoma
Bommareddy, P. K., Silk, A. W., & Kaufman, H. L. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000234 · Cited by 58
Self-citationGrekova, S. P., Aprahamian, M., Giese, N. A., Schmitt, S., Giese, T., Falk, C. S., Daeffler, L., Cziepluch, C., Rommelaere, J., & Raykov, Z. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.12.13455 · Cited by 50 · cited 1×
“This type of nonapoptotic death is immunogenic and through a bystander effect, leads to an increase of interferon (IFN)-γ, inflammatory cytokines, and tumor neoantigen exposure from oncolytic cell death, which together, can lead to antitumor immune responses (46, 47).”
BackgroundPuzanov, I. J., Milhem, M. M., Andtbacka, R. H. I., Minor, D. R., Hamid, O., Ai, L., Chou, J., & Kaufman, H. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9063 · Cited by 46 · cited 2×
“T-VEC is now being tested in other cancers and in rational combinations with standard and immune-targeted therapies (9, 18).”
BackgroundTalimogene laherparepvec (T-VEC) as cancer immunotherapy
Kohlhapp, F. J., Zloza, A., & Kaufman, H. L. (2015) · Drugs of today · doi:10.1358/dot.2015.51.9.2383044 · Cited by 45
Self-citationArlen, P. M., Pazdur, M. P., Skarupa, L., Rauckhorst, M., & Gulley, J. L. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.032 · Cited by 40
Andtbacka, R. H. I., Curti, B. D., Hallmeyer, S., Feng, Z., Paustian, C. C., Bifulco, C. B., Fox, B. A., Grose, M., & Shafren, D. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p343 · Cited by 39
Sosna, J., Philipp, S., Chico, J. F., Saggau, C., Fritsch, J., Föll, A., Plenge, J., Arenz, C., Pinkert, T., Kalthoff, H., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00941-15 · Cited by 39
Lawson, K. A., Mostafa, A., Shi, Z. Q., Spurrell, J. C. L., Chen, W., Kawakami, J., Gratton, K., Thakur, S. S., & Morris, D. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0143 · Cited by 38
Silk, A. W., Kaufman, H., Gabrail, N., Mehnert, J., Bryan, J., Norrell, J., Medina, D., Bommareddy, P., Shafren, D., Grose, M., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct026 · Cited by 36
Self-citationWilkinson, M., Smith, H. G., McEntee, G., Kyula, J., Pencavel, T. D., Mansfield, D., Khan, A., Roulstone, V., Hayes, A. J., & Harrington, K. J. (2016) · Oncotarget · doi:10.18632/oncotarget.12820 · Cited by 31
Immunotherapy in Cancer Treatment
Smith, A., Oertle, J. C., III, & Prato, D. (2014) · Open Journal of Medical Microbiology · doi:10.4236/ojmm.2014.43020 · Cited by 8 · cited 1×
“In contrast, immunotherapy seeks to enhance the host immune system’s ability to eliminate cancer cells resulting in tumor regression, antitumor immune memory formation, and ultimately in durable responses (1, 2).”
Background
Cited by
Oncolytic viruses for cancer immunotherapy
Hemminki, O., dos Santos, J. M., & Hemminki, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00922-1 · Cited by 351
Combination Therapies for the Optimisation of Bispecific T-Cell Engagers in Cancer Treatment
Zhu, W. M., & Middleton, M. R. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad013 · Cited by 46
Metadata
- Authors
- Jhawar, S. R., Thandoni, A., Bommareddy, P. K., Hassan, S., Kohlhapp, F. J., Goyal, S., Schenkel, J. M., Silk, A. W., & Zloza, A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2017-09-11
- Volume
- 7
- Pages
- 202-202
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2755866843
- Cited by
- 178
- References
- 73
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.